Femasys Inc.

Equities

FEMY

US31447E1055

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.27 ^USD	-4.51%		-3.79%	+30.26%

Apr. 01	HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating	MT
Mar. 28	Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors

November 21, 2023

On November 22, 2023, Femasys Inc. closed the transaction. The company received $1,850,000 in its second and final tranche. The company received funding pursuant to Regulation D in the transaction from 4 investors.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	PHARMACYTE BIOTECH, INC.	2.11 USD	-0.47%	-0.47%	17.84M
	FEMASYS INC.	1.27 USD	-4.51%	-3.79%	28.07M

Latest news about Femasys Inc.

HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating	Apr. 01	MT
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	Mar. 20	CI
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	Mar. 06	CI
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer	Feb. 06	CI
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial	Jan. 26	MT
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women	Jan. 26	CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah	Jan. 23	CI
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine	Dec. 15	CI
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer	Nov. 30	CI
Femasys Inc. Completes Enrollment of Femaseed Pivotal Trial in Support of Commercial Launch	Nov. 29	CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors	Nov. 21	CI
Femasys Inc. Appoints Joshua Silverman as Director	Nov. 21	CI
Femasys Inc. announces tranche update	Nov. 16	CI
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186	Nov. 14	MT
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.	Nov. 13	CI
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation	23-10-26	CI
Top Premarket Decliners	23-10-04	MT
Top Midday Gainers	23-09-29	MT
HC Wainwright Raises Femasys' Price Target to $13 From $5, Keeps Buy Rating	23-09-29	MT
Top Midday Decliners	23-09-27	MT
Femasys Activates Enrollment in Trial of FemBloc Birth Control Candidate	23-09-27	MT
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate	23-09-27	CI
Top Premarket Decliners	23-09-27	MT

Chart Femasys Inc.

Duration

Period

More charts

Company Profile

Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physicianâs office setting.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Femasys Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.27 USD

Average target price

9.75 USD

Spread / Average Target

+667.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
FEMASYS INC.	+30.26%	28.07M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution